DBV, Stallergenes in $198M Pact on Birch Pollen Allergy Therapy
Shares in DBV Technologies SA gained more than 9 percent Friday on news of a licensing deal on a treatment for birch (Betula verrucosa) pollen allergy with Stallergenes SA, which is worth up to €145 million (US$198 million) in milestone payments, as well as royalties on potential product sales.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter